Induction of MAGE-3 expression in lung and esophageal cancer cells.
about
Epigenetic therapy in gastrointestinal cancer: the right combinationCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementIneffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Decitabine: a review of its use in older patients with acute myeloid leukaemia.Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphomaNYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)The role of quantitative PCR for the immune monitoring of cancer patients.Augmenting antitumor immune responses with epigenetic modifying agents.De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.MAGE-A Antigens and Cancer Immunotherapy.The biology of cancer testis antigens: putative function, regulation and therapeutic potentialCutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Epigenetics of melanoma: implications for immune-based therapies.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers.MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer.Epigenetically regulated tumor-associated antigens in melanoma
P2860
Q26745709-D2C416F3-83FB-4918-9402-E486E39F4C17Q27024076-839582A0-EF8A-4D6F-8AC2-B9C653CF5483Q30310695-E5D0FA7D-1EA5-4953-8634-1546D3779AECQ33390876-2B646D89-6431-4F60-838B-2755BAFB0F95Q33407030-581A498F-5F72-4E45-834A-1B5E96DF54BBQ33726989-10DA41EA-E386-45A5-996E-02F85AF73792Q34182308-A799EA0E-B0D2-412A-87BE-92C3EF5C40FBQ34510205-A85289F0-4B6B-4EC4-9E68-356565D767E0Q34701413-11A037EF-5E75-4D65-A53C-A640DD79EF0FQ35048054-3253B0A7-2820-4BD3-AB34-C8504DB71AE6Q36459332-F8B254AD-B273-4850-8B9B-C92B85729F62Q36470196-F3E2D0F0-9206-45D8-8DF9-713CC3B6F5FFQ36801625-A2346D30-0EA2-49A6-A912-2CA255A12464Q37685379-D85BF009-CA97-48DB-8709-854701828AF4Q37849976-0E1E7BCB-3374-4610-B870-136A19AEAEE7Q37944565-24AE053F-B94D-46EA-99B4-BEEAC66FBD86Q38148588-2FFC14E2-A0BA-44D9-ACBD-D6699A01DED4Q38314204-A5FC0FE2-4797-4A7A-96C4-F029724B3217Q39247530-B9D60F1C-82C4-45BB-A6BC-4133F650DE0DQ39546197-848DEB17-F541-44E6-BAF9-B2EDF31EF1B7Q40663897-07D72080-C6FB-434A-A8F0-D5327AA96BDCQ48030870-FCFE870A-3A38-4ED2-9A46-85DB7FDD9297Q48034709-D785075A-7997-4BD2-9FB9-963A69EE39DAQ50252299-18AB5A3D-27B7-4621-8523-B20C9EC4F6A4Q54946747-A8575E2C-D476-4A01-9F88-F73D7ABDBEC7Q57570339-A54B47CF-F6AA-4B45-8112-ADFCFC1E170F
P2860
Induction of MAGE-3 expression in lung and esophageal cancer cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Induction of MAGE-3 expression in lung and esophageal cancer cells.
@ast
Induction of MAGE-3 expression in lung and esophageal cancer cells.
@en
type
label
Induction of MAGE-3 expression in lung and esophageal cancer cells.
@ast
Induction of MAGE-3 expression in lung and esophageal cancer cells.
@en
prefLabel
Induction of MAGE-3 expression in lung and esophageal cancer cells.
@ast
Induction of MAGE-3 expression in lung and esophageal cancer cells.
@en
P2093
P1476
Induction of MAGE-3 expression in lung and esophageal cancer cells.
@en
P2093
D M Nguyen
D S Schrump
G A Ohnmacht
M R Fischette
T S Weiser
P304
295-301; discussion 301-2
P356
10.1016/S0003-4975(00)02421-8
P407
P577
2001-01-01T00:00:00Z